This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 825673.
CARE (Common Action against HIV/TB/HCV across the Regions of Europe) aims at analysing and addressing the human immunodeficiency virus (HIV), tuberculosis (TB) and hepatitis C (HCV) epidemics across Europe and Russia, by establishing new networks and consolidating previous cooperative actions between the European Union and the Russian Federation.
The project will generate novel research findings based on existing biological material and data already collected by the participating partners, as well as on new samples and data gathered during the project.
Restricted
Access Area
CARE HIV-TB-HCV: EU-Russia cooperation results
Online conference - June 15
HIV-TB-HCV: EU-Russia cooperation results
15 June 2021, 9:00 – 16:00 CEST
The online meeting organised by the CARE Consortium had the objective to present and discuss outcomes and findings from CARE Common Action and other projects and initiatives in the frame of recent collaborative research in the WHO European Region.
It has seen the participation of CARE, ARREST-TB, CARE External Scientific Advisory Board, CARE External Ethics Review Board, Russian experts, NDPHS, Russian Ministry of Health, Russian Ministry of Science and Higher Education, EC, EU Delegation to the Russian Federation.
Here you can find the Programme. More info and materials at the Conference page.
CARE DBs
latest enrolment updates
CARE NEWS
Whole genome metagenomic analysis of the gut microbiome in HIV-1 infected individuals on antiretroviral therapy
Bai X, Narayanan A, Nowak P, Ray S, Neogi U, Sönnerborg A. Front Microbiology 2021, accepted 2021-05-31, DOI: 10.3389/fmicb.2021.667718
CARE NEWS
Dissemination of Mycobacterium tuberculosis is associated to a SIGLEC1 null variant that limits antigen exchange via trafficking extracellular vesicles
Gálvez SBC, Drobniewski F, Kontsevaya I, Arias L, Monguió‐Tortajada M, Erkizia I, Urrea V, Ong RY, Luquin M, Dupont M, Chojnacki J, Dalmau J, Cardona P, Neyrolles O, Lugo‐Villarino G, Vérollet C, Julián E, Furrer H, Günthard HF, Crocker PR, Tapia G, Borràs FE, Fellay J, McLaren PJ, Telenti A, Cardona PJ, Clotet B, Vilaplana C, Martinez‐Picado J, Izquierdo‐Useros N, Journal of Extracellular Vesicles. 14 January 2021
CARE NEWS
CARE NEWS
High-throughput sequencing reveals a high prevalence of pretreatment HIV-1 drug resistance in Sweden
,
Andersson E, Ambikan A, Brännström J, Aralaguppe SG, Yilmaz A, Albert J, Neogi U, Sönnerborg A., AIDS. 2021 Feb 2;35(2):227-234. doi: 10.1097/QAD.0000000000002740. PMID: 33394670.
Genetic Profile of HIV-1 in the Vologda Region: Domination of CRF03_AB and Rapid Distribution of URFs. Ozhmegova EN, Antonova AA, Lebedev AV, Melnikova TN, Krylova TV, Kazachek AV, Shiryaeva NA, Kirillova IL, Kazennova EV, Bobkova MR (2020)
HIV infection and immunosuppressive disorders. 2020. Vol. 12, No. 2. pp. 79-88
CARE NEWS
Susceptibility to HIV - integrase inhibitors in HIV-1 sub subtype A6 isolates
Giannini A, Giammarino F, Antonova A, Ozhmegova E, Kaiser R, Dragoni F, Boccuto A, Vicenti I, Sönnerborg A, Bobkova M, Zazzi M, Saladini F
Poster presented at the ICAR Conference, 12-16 October 2020; accepted among the poster session "Best of Posters" at the virtual 18th European Meeting on HIV & Hepatitis, October 28-30, 2020.
CARE NEWS
3 posters presented at the 18th European meeting on HIV and hepatitis, 28-30 October 2020
A changing of HIV-1 genetic diversity in Russia during the last two decades: increase of the recombinants prevalence,
Antonova A, Kazennova E, Bobkova M
The efficacy of first-line therapy based on RPV in HIV-infected patients with pre-existing E138A mutation in reverse transcriptase, Kuznetsova A., Gromov K. , Kazennova E., Bobkova M. Maurizio Zazzi, Francesca Incardona, Anders Sönnerborg
Prevalence and spatiotemporal dynamics of the HIV-1 circulating recombinant form 03_AB (CRF03_AB) in the former Soviet Union, Ozhmegova E, Lebedev A, Pasechnik O, Blokh A, Grezina L, Dementeva N, Sandyreva T, Kazennova E and Bobkova M
CARE NEWS
CARE NEWS
In vitro cross-resistance to doravirine in a panel of HIV-1 clones
harbouring multiple NNRTI resistance mutations
,
Saladini F, Giammarino F, Hosseini BA, Giannini A, Boccuto A,
Dragoni F, Vicenti I, Shafer RW and Zazzi M (2020), J Antimicrob Chemother, doi:10.1093/jac/dkaa401
CARE NEWS
HIV-1 Sub-Subtype A6: Settings for Normalised Identification and Molecular Epidemiology in the Southern Federal District, Russia
Schlösser M, Kartashev VV, Mikkola VH, Shemshura A, Saukhat S, Kolpakov D, Suladze A, Tverdokhlebova T,
Hutt K, Heger E, Knops E, Böhm M, Di Cristanziano V, Kaiser R, Sönnerborg A, Zazzi M, Bobkova M and Sierra S. Viruses 2020, 12, 475; doi:10.3390/v12040475
CARE NEWS
“Joint efforts against infectious diseases: HIV, TB, HCV”
Moscow, 27th January 2020
Held with success the high level conference in Moscow
at the presence of the EU ambassador in Russia Mr Ederer, of the First Deputy Minister of the Ministry of Science and Higher Education of the Russian Federation Mr Trubnikov, and of the high representative of the Ministry of Health of the Russian Federation Mr Kostennikov,
The CARE and the ARREST-TB projects presented their interim results and fuelled a lively scientific discussion in a cooperative atmosphere.
CARE NEWS
TRAINING ACTIVITIES AT SIENA UNIVERSITY
December 2019
Capacity-building activities of the CARE project have started at Siena University: a group of researchers from the Gamaleya Center (Russia) are now hosted in Italy for attending training modules, coordinated by Prof. Zazzi.
FIRST SAMPLES FROM RUSSIA TO EUROPE!
December 2019
Thanks to the data and samples sharing infrastructure created by the CARE partners, since December 2019 samples from Russia are being delivered to Cologne University (Germany), Karolinska Institute (Sweden) and Siena University (Italy). An official channel for the exchange of biological material is set up among European and Russian centers for research purposes: another successful step toward the network of collaboration against HIV, TB and HCV.
